Technology Innovation Institute (TII) and Burjeel Medical City (BMC) are partnering to develop novel immunotherapy solutions for cancer treatment, focusing on T-cell based therapeutics like CAR-T and TIL therapy. In the first phase, TII will construct a computational platform to identify patient-specific antigens from single-cell transcriptomics data, enabling the design of CAR-T cells. The two-year partnership aims to boost the body's immune system to fight cancer and personalize cancer therapies using TII's technologies. Why it matters: This collaboration signifies the UAE's commitment to advancing cancer care through collaborative research and innovative solutions, potentially establishing the country as a leader in personalized oncology treatments.
The Technology Innovation Institute (TII) in Abu Dhabi has launched a 2-micrometer high-power fiber laser for medical and industrial applications. Developed by TII's Directed Energy Research Center, the Thulium-based laser is efficient, compact, and scalable, enabling precise interaction with water-rich materials. TII has partnered with LIMA Photonics, a German MedTech startup, to integrate the laser into clinical solutions, including urinary stone treatment and prostate surgery. Why it matters: This laser technology and partnership showcase the UAE's commitment to translating advanced research into healthcare solutions, positioning Abu Dhabi as a hub for medical technology innovation.
MBZUAI researchers are refining AI techniques to improve cancer diagnosis for colorectal and breast cancer, both common in the Middle East. They are using "few-shot tissue image generation," in which AI generates data for training AI models to recognize lesions, addressing the challenge of limited training data. The developed framework improves the efficiency of radiologists in breast cancer diagnosis, leading to better detection of breast lesions and timely treatment interventions. Why it matters: These advancements in AI-aided diagnostics can lead to earlier and more accurate cancer detection, ultimately improving patient outcomes in the region and beyond.
The Technology Innovation Institute (TII) and NYU Abu Dhabi (NYUAD) have signed a collaboration agreement to deepen strategic collaboration in research, education, and talent development. The partnership includes a Research and Development Sponsorship Agreement and a Framework Fellowship Program Agreement. TII and NYUAD will collaborate on joint research projects across areas like AI, robotics, and quantum science, and TII will sponsor NYUAD students for research in priority technology domains. Why it matters: The partnership aims to bridge fundamental research with real-world applications, accelerate scientific discovery, and develop a pipeline of skilled researchers in Abu Dhabi.
The Technology Innovation Institute (TII) in Abu Dhabi has launched a Biofoundry to advance R&D in synthetic biology, focusing on genetic engineering, metabolic engineering, and bioinformatics. The facility features high-throughput robotic systems, next-generation sequencing, and advanced computational tools. TII's Biofoundry is now part of the Global Biofoundry Alliance (GBA) to foster partnerships and address shared challenges. Why it matters: This initiative positions the UAE as a key player in synthetic biology, with potential breakthroughs across healthcare, agriculture, and environmental sustainability.